Wells Fargo maintains RxSight at Equal-Weight, lowers price target to $6 from $9

What happened

Wells Fargo kept its Equal-Weight rating on RxSight and cut its price target to $6 from $9, a 33.3% decrease. The new target implies 30.7% upside from RxSight’s November 3 closing price of $4.59.

Confirmed

Global impact / market context

The lower target signals that Wells Fargo sees less potential value in RxSight than before, even while retaining its Equal-Weight rating. If investors adjust expectations toward the new target, their willingness to buy or hold the shares could change, affecting demand for the stock.

Analyst inference

The article reports one analyst’s rating and target change, not a company forecast or a broader industry view. The target remains above the cited closing price, but that implied upside is an estimate, not a promised return or evidence of future performance.

Analyst inference

What to watch

1. Check whether Wells Fargo explains its lower target in later commentary; the article gives no reason, and the rationale could clarify which business assumptions changed. Analyst inference
2. Compare future analyst ratings and targets with this $6 target to see whether expectations converge or diverge; the article does not report other analysts’ views. Analyst inference
3. Watch RxSight’s reported results and outlook for changes in revenue, costs, or cash available that could support or challenge the assumptions behind analysts’ valuations. Analyst inference

Evidence

• Original source link unavailable